Watching a Procedure Evolve: Sequential Findings From the TVT Registry

摘要

Transcatheter aortic valve replacement (TAVR) has rapidly expanded in the United States and worldwide. The approval of the first 2 TAVR prostheses in the United States is based on data from randomized trials showing survival rates superior to conservative medical therapy in nonoperable patients [1, 2] and comparable or superior to surgical aortic valve replacement (SAVR) for patients at high surgical risk [3, 4]. Data from these trials have now been extended to 5-year outcomes for the PARTNER (Placement of Aortic Transcatheter Valves) trial and 2-year outcomes for the CoreValve trial, and continue to confirm the initial findings [5–8].